Ricevi le ultime notizie sulle azioni Ventyx Biosciences con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di VTYX

Ultime notizie per

VENTYX BIOSCIENCES INC

Ventyx Biosciences

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Ventyx Biosciences Inc

Press Releases

General

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

News

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Earnings

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Management

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Health Care

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

VTYX

Aardvark Therapeutics, Inc. - Common Stock

Aardvark Therapeutics

Aurora Cannabis

Aclaris Therapeutics, Inc. - Common Stock

Aclaris Therapeutics

Alumis

ALT5 Sigma

Atea Pharmaceuticals, Inc. - common stock

Atea Pharmaceuticals

Bioage Labs

Cognition Therapeutics, Inc. - Common Stock

Cognition Therapeutics

Contineum Therapeutics, Inc. - Common stock

Contineum Therapeutics

Cybin

Journey Medical Corporation - Common Stock

Journey Medical

Evolus

High Tide

LB Pharmaceuticals

MediWound

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies Hldgs

Organigram Global

Omeros

Cassava Sciences

Scilex Holding

scPharmaceuticals

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

Tvardi Therapeutics

Clear Street

Oppenheimer

Wells Fargo

Canaccord Genuity

Stifel

Comments

Ventyx Biosciences Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO